Related Experiment Video
Updated: Jul 19, 2026
12:27
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Targeting sphingosine-1-phosphate for cancer therapy
1Department of Biology, San Diego State University, 5500 Campanile Dr, San Diego, CA 92182-4614, USA. rsabba@sunstroke.sdsu.edu
British Journal of Cancer
|October 7, 2006
Summary
Sphingosine-1-phosphate (S1P) promotes tumor growth and blood vessel formation. Targeting S1P and other lipid molecules offers a new therapeutic strategy for cancer and other diseases.
Area of Science:
- Oncology
- Lipidomics
- Molecular Biology
Background:
- Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator.
- Tumor microenvironments are complex and influenced by secreted factors.
- Cancer progression involves angiogenesis and tumor growth.
Purpose of the Study:
- To review new findings on S1P's role in tumorigenesis and angiogenesis.
- To explore S1P as a potential drug target in oncology.
- To introduce lipidomic-based therapeutics for cancer treatment.
Main Methods:
- Literature review of recent studies on S1P.
- Analysis of S1P's function in the tumor microenvironment.
- Discussion of drug design strategies targeting lipid signaling.
Main Results:
- S1P is implicated as a key factor in promoting tumor growth.
- S1P acts as a potent angiogenic agent in the tumor microenvironment.
- Bioactive lipids like S1P represent novel targets for drug development.
Conclusions:
- S1P plays a significant role in cancer progression.
- Targeting S1P offers a promising therapeutic avenue in oncology.
- Lipidomic-based therapies hold potential for treating various human diseases.
